Longeveron(LGVN)
MIAMI, FLBiotechnology
Focus: Longeveron is a public biotech focused on allogeneic mesenchymal stem cell (MSC) therapies targeting aging-related diseases including Alzheimer's, frailty, and congenital heart conditions. The company is early-stage with minimal revenue ($2M in FY2025) and operates from Miami with a clinical-stage pipeline.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Longeveron
AI assessmentNot HiringNo open roles listed right now. Follow Longeveron to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Longeveron's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
10 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$2M
Pipeline & Clinical Trials
Longeveron Mesenchymal Stem Cells
Alzheimer's DiseaseClinical Trials (1)
NCT02600130Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease
Phase 1Help build intelligence for Longeveron
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.